Heteroaryl-fused pyrimidinyl compounds as anticancer agents
US7345046B2 · kind B2 · utility
19Cited by
0References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2004 |
| Grant date | Mar 18, 2008 |
| Priority date | — |
| Expiry date | Jan 4, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.